
Opinion|Videos|November 4, 2024
Community Oncologist Perspective: Protocol Development for Bispecific Administration and AE Management
Dr Graff discusses how they developed protocols for administering bispecific antibodies and monitoring and managing associated adverse events.
Advertisement
Video content above is prompted by the following:
How did you develop your administration and adverse event monitoring and management protocols?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment
4
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
5
















